NASDAQ:EFTR eFFECTOR Therapeutics (EFTR) Stock Price, News & Analysis $0.0002 0.00 (0.00%) As of 07/23/2025 12:08 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About eFFECTOR Therapeutics Stock (NASDAQ:EFTR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get eFFECTOR Therapeutics alerts:Sign Up Key Stats Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.00▼$0.06Volume150 shsAverage Volume3,005 shsMarket Capitalization$940.80P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California. Read More eFFECTOR Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreEFTR MarketRank™: eFFECTOR Therapeutics scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for eFFECTOR Therapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of eFFECTOR Therapeutics is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about eFFECTOR Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted0.13% of the float of eFFECTOR Therapeutics has been sold short.Short Interest Ratio / Days to CovereFFECTOR Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldeFFECTOR Therapeutics does not currently pay a dividend.Dividend GrowtheFFECTOR Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.13% of the float of eFFECTOR Therapeutics has been sold short.Short Interest Ratio / Days to CovereFFECTOR Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous month News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for EFTR on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, eFFECTOR Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of eFFECTOR Therapeutics is held by insiders.Percentage Held by Institutions57.67% of the stock of eFFECTOR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about eFFECTOR Therapeutics' insider trading history. Receive EFTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for eFFECTOR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address EFTR Stock News HeadlineseFFECTOR Therapeutics (OTC:EFTR) Stock, Insider Trading ActivityOctober 5, 2024 | benzinga.com3 Publicly Traded Companies Filing for Bankruptcy as July Kicks OffJuly 15, 2024 | investorplace.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 25 at 2:00 AM | Brownstone Research (Ad)eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from NasdaqJune 24, 2024 | globenewswire.comeFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian CancerMay 20, 2024 | globenewswire.comEFTR Stock Earnings: eFFECTOR Therapeutics Meets EPS for Q1 2024May 9, 2024 | investorplace.comeFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 9, 2024 | globenewswire.comeFFECTOR Therapeutics to Participate in Upcoming Investor ConferenceApril 9, 2024 | globenewswire.comSee More Headlines EFTR Stock Analysis - Frequently Asked Questions How have EFTR shares performed this year? eFFECTOR Therapeutics' stock was trading at $0.0002 at the beginning of the year. Since then, EFTR shares have increased by 0.0% and is now trading at $0.0002. How were eFFECTOR Therapeutics' earnings last quarter? eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) posted its quarterly earnings data on Monday, November, 8th. The company reported $10.50 EPS for the quarter, beating the consensus estimate of ($6.50) by $17.00. The firm earned $0.43 million during the quarter. When did eFFECTOR Therapeutics' stock split? eFFECTOR Therapeutics's stock reverse split before market open on Friday, January 12th 2024.The 1-25 reverse split was announced on Friday, January 12th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 12th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of eFFECTOR Therapeutics? Shares of EFTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of eFFECTOR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that eFFECTOR Therapeutics investors own include HubSpot (HUBS), Netflix (NFLX), Tesla (TSLA), Athenex (ATNX), ForgeRock (FORG) and Plug Power (PLUG). Company Calendar Last Earnings11/08/2021Today7/25/2025Next Earnings (Estimated)7/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EFTR CIK1828522 Webwww.locustwalkacquisitioncorp.com Phone858-925-8215FaxN/AEmployees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.94) per share Price / Book0.00Miscellaneous Outstanding Shares4,704,000Free Float4,483,000Market Cap$940.80 OptionableNo Data Beta1.00 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:EFTR) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
